| scholarly article | Q13442814 |
| P50 | author | Markus Reindl | Q37383284 |
| Monika Haemmerle | Q45869625 | ||
| P2093 | author name string | Thomas Berger | |
| Michael Schocke | |||
| Andreas Lutterotti | |||
| Bettina Kuenz | |||
| Florian Deisenhammer | |||
| Claudia Gneiss | |||
| Rainer Ehling | |||
| Carolyn Rainer | |||
| P2860 | cites work | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 |
| Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis | Q28293364 | ||
| The immunopathology of multiple sclerosis: an overview | Q28295115 | ||
| Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development | Q28585776 | ||
| Restricted use of VH4 germline segments in an acute multiple sclerosis brain | Q32107477 | ||
| Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis | Q34098936 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement | Q36163180 | ||
| Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
| B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation | Q36485715 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. | Q51979636 | ||
| Immune surveillance in multiple sclerosis patients treated with natalizumab. | Q54606407 | ||
| Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. | Q54759503 | ||
| Unveiling the enigma of the CNS as a B-cell fostering environment | Q61657776 | ||
| The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis | Q73536622 | ||
| Immunology of multiple sclerosis | Q81531267 | ||
| Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. | Q37285430 | ||
| Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. | Q37385073 | ||
| Expression of matrix metalloproteinases by human plasma cells and B lymphocytes | Q41030038 | ||
| B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions | Q41697260 | ||
| Matrix metalloproteinases and diseases of the CNS. | Q41719486 | ||
| T cell gelatinases mediate basement membrane transmigration in vitro. | Q42485012 | ||
| Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients | Q42619341 | ||
| Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | Q45119459 | ||
| Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection | Q45401097 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. | Q47760934 | ||
| Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods | Q47857522 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis | Q48316904 | ||
| Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination | Q48489118 | ||
| Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis | Q48547710 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Cortical demyelination and diffuse white matter injury in multiple sclerosis. | Q48726181 | ||
| Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis | Q48949365 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| encephalitis | Q199615 | ||
| multiple sclerosis | Q8277 | ||
| cerebrospinal fluid | Q54196 | ||
| inflammation | Q101991 | ||
| P304 | page(s) | e2559 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis | |
| P478 | volume | 3 |
| Q56688690 | A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands |
| Q45865616 | Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121. |
| Q54538706 | Antimyelin antibodies as predictors of disability after clinically isolated syndrome. |
| Q37400354 | B cell characterization and reactivity analysis in multiple sclerosis |
| Q38050398 | B cells and antibodies in multiple sclerosis pathogenesis and therapy |
| Q37530897 | B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis |
| Q51033051 | B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset |
| Q42873734 | Baicalein Significantly Protects Human Retinal Pigment Epithelium Cells Against H2O2-Induced Oxidative Stress by Scavenging Reactive Oxygen Species and Downregulating the Expression of Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor |
| Q27496017 | Biomarkers in Multiple Sclerosis: An Up-to-Date Overview |
| Q28305094 | Biomarkers of treatment response in multiple sclerosis |
| Q39148044 | Brain inflammation is accompanied by peripheral inflammation in Cstb (-/-) mice, a model for progressive myoclonus epilepsy. |
| Q41255081 | Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. |
| Q39808939 | Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. |
| Q48482480 | Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis |
| Q38088728 | Clinical biomarkers in multiple sclerosis |
| Q36202928 | Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. |
| Q47935420 | Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. |
| Q24273331 | Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases |
| Q26740330 | Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis |
| Q35689190 | Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis |
| Q50864411 | Detection of B-cell populations with monotypic light chain expression in cerebrospinal fluid specimens from patients with multiple sclerosis by polychromatic flow cytometry. |
| Q59333230 | Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid |
| Q33700802 | Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients. |
| Q34658981 | Epstein-Barr virus in multiple sclerosis |
| Q40749805 | Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression. |
| Q37875022 | Flow cytometric characterization of cerebrospinal fluid cells |
| Q35149579 | Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients |
| Q51049988 | Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. |
| Q33911364 | High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years. |
| Q36094995 | High-quality full-length immunoglobulin profiling with unique molecular barcoding. |
| Q35848490 | Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis |
| Q59273778 | Immunohistochemistry |
| Q34718044 | Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. |
| Q92904423 | Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS |
| Q26851694 | Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments |
| Q82271563 | Intrathecal immune responses to EBV in early MS |
| Q37763624 | Intrathecal methotrexate treatment in multiple sclerosis |
| Q34980198 | MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. |
| Q46054080 | Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. |
| Q21558407 | Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone |
| Q48349615 | Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model |
| Q58034049 | Predictable Irreversible Switching Between Acute and Chronic Inflammation |
| Q31139925 | Progressive multiple sclerosis: from pathogenic mechanisms to treatment. |
| Q34684427 | Secondary B cell receptor diversification is necessary for T cell mediated neuro-inflammation during experimental autoimmune encephalomyelitis |
| Q35242883 | Street-experienced peripheral B cells traffic to the brain |
| Q61818118 | The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis |
| Q33654152 | The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). |
| Q37993033 | The evidence for a role of B cells in multiple sclerosis |
| Q47639897 | Western lifestyle and immunopathology of multiple sclerosis |
| Q51958899 | [Targeting B cells in multiple sclerosis. Current concepts and strategies]. |
Search more.